CVS Health Corp. on November 3 said the company’s adjusted profit target for 2022 should largely meet Wall Street estimates, with volatile medical costs in its health insurance unit expected to stabilize after the Covid-19 crisis drove them up during 2021.

A syringe and vial are seen in front of a displayed Pfizer logo in this illustration taken June 24, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Pfizer Inc. on Nov. 2 said the company expected 2021 sales of the Covid-19 vaccine developed with German partner BioNTech SE would reach $36 billion and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.

AbbVie Inc. on Oct. 29 raised the company’s 2021 adjusted profit forecast for the third time this year after a stellar performance by newer medicines helped the U.S. drugmaker beat Wall Street estimates for third-quarter profit and revenue.

Johnson & Johnson on Oct. 19 reported lower-than-expected quarterly revenue after sales of the company’s Covid-19 vaccine missed Wall Street estimates following a string of production setbacks.

The pandemic is pushing more people to seek treatment for obesity, Novo Nordisk’s top boss said on Aug. 5, referring to strong sales of the newly launched drug Wegovy, which helped the drugmaker raise its earnings forecast for full-year 2021.

Sanofi raised the company’s 2021 profit forecast on July 29 after its vaccines and star eczema treatment Dupixent helped the French drugmaker beat second-quarter results expectations.

Pfizer Inc. on July 28 raised the 2021 sales forecast for the company’s Covid-19 vaccine by 29 percent to $33.5 billion, and said the drugmaker believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.

Pfizer reported first-quarter 2021 revenue of $14.6 billion, an impressive 42 percent operational growth. The company’s Covid-19 vaccine revenue accounted for $3.5 billion of the total.

Merck

Merck & Co. Inc. said on April 29 the company would take a bigger hit to sales during 2021 than previously expected due to a resurgence in Covid-19 cases that has hurt demand for drugs that need to be given by doctors.

Amgen

U.S. biotech Amgen Inc. provided a 2021 earnings forecast below Wall Street estimates and said the company paused or halted enrollment for clinical trials of three cancer drugs.